New protein-targeting drug shows promise in early trial for patients with high-risk CLL
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL), according to a study led in part by ...
Cancer
May 17, 2013 |
not rated yet |
0
|
Researchers discover master regulator that drives majority of lymphoma
A soon-to-be-tested class of drug inhibitors were predicted to help a limited number of patients with B-cell lymphomas with mutations affecting the EZH2 protein. However, a research team, led by investigators at Weill Cornell ...
Cancer
May 13, 2013 |
5 / 5 (2) |
0
|
Searching for therapeutic synergy in primary effusion lymphoma
Primary effusion lymphoma (PEL) is a rare, fatal form of aggressive B-cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV). The disease most commonly occurs in immunocompromised patients, such as those with ...
Cancer
May 01, 2013 |
not rated yet |
0
Immunotherapy showed promising antileukemia activity in pediatric patients
Researchers using patients' own immune cells in an immunotherapy approach called "anti-CD19 chimeric antigen receptor (CAR) T-cell therapy," achieved responses in children whose acute lymphocytic leukemia (ALL) had returned ...
Cancer
Apr 07, 2013 |
5 / 5 (1) |
0
New type of deadly lymphoma identified
An international research team has identified a new type of deadly intestinal lymphoma that is particularly common in Asia. The team, led by clinician-scientists from the SingHealth Academic Healthcare Cluster, also developed ...
Cancer
Apr 01, 2013 |
5 / 5 (2) |
0
Researchers find NSAIDs help push stem cells into bloodstream prior to transplantation
(Medical Xpress)—A team of researchers at Indiana University's School of Medicine has found that giving meloxicam, a non-steroidal anti-inflammatory drug (NSAID), to people and baboons boosts the number of haematopoietic ...
Medical research
Mar 14, 2013 |
not rated yet |
0
|
Study finds how to shutdown cancer's powerful master protein
The powerful master regulatory transcription factor called Bcl6 is key to the survival of a majority of aggressive lymphomas, which arise from the B-cells of the immune system. The protein has long been considered too complex ...
Immunology
Mar 03, 2013 |
5 / 5 (6) |
0
|
Small molecules in the blood might gauge radiation effects after exposure
Ohio State University cancer researchers have identified molecules in the bloodstream that might accurately gauge the likelihood of radiation illness after exposure to ionizing radiation.
Cancer
Feb 25, 2013 |
5 / 5 (1) |
0
|
Team finds general mechanism that accelerates tumor development
ICREA professor Raúl Méndez publishes a study in Nature describing how the CPBE1 protein "takes the brakes off" the production of proteins associated with the cell switch from being healthy to tumorous. ...
Cancer
Feb 24, 2013 |
5 / 5 (3) |
0
Experimental drug combination selectively destroys lymphoma cells
Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an effective ...
Cancer
Feb 06, 2013 |
4.5 / 5 (2) |
0
|
High-dose Vorinostat effective at treating relapsed lymphomas
Patients whose aggressive lymphomas have relapsed or failed to respond to the current front-line chemotherapy regimen now have an effective second line of attack against their disease. Reporting the results of a first-of-its-kind ...
Cancer
Feb 04, 2013 |
not rated yet |
0
Discovery of new class of damage-prone DNA regions could lead to better cancer treatments
Cancer is thought to arise from DNA damage at fragile sites in the genome. A study published by Cell Press on January 24th in the journal Cell reveals a new class of fragile sites that contributes to DNA ...
Cancer
Jan 24, 2013 |
5 / 5 (1) |
0
|
Gold nanoparticles show new way to kill lymphoma without chemotherapy
How do you annihilate lymphoma without using any drugs? Starve it to death by depriving it of what appears to be a favorite food: HDL cholesterol.
Cancer
Jan 21, 2013 |
4.9 / 5 (15) |
1
|
Epigenomic abnormalities predict patient survival in non-Hodgkins lymphoma
Think of the epigenome like a giant musical mixing board, turning up or down the expression of various genes. A University of Colorado Cancer Center study published today in the journal PLOS Genetics shows that in cancer ...
Genetics
Jan 10, 2013 |
not rated yet |
0
|
New pill holds promise for fewer side effects in treating leukemia
(Medical Xpress)—An international team of researchers has developed a new anti-cancer drug that holds promise as a therapy that fights cancer while causing fewer side effects than current medicines. The ...
Cancer
Jan 07, 2013 |
5 / 5 (3) |
0
|
